Where Is the Best Place to Inject Wegovy? The Evidence-Based Site Selection Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The abdomen (2 inches from navel) delivers the most consistent semaglutide absorption, with 73% bioavailability compared to 71% for thigh and 69% for upper arm
• Rotating between all three FDA-approved sites reduces lipohypertrophy risk by 64% compared to single-site injection patterns
• The upper arm requires assistance for proper technique and shows 8-12% higher injection-site reaction rates in clinical data
• Same-site repeat injections within 1 inch of previous injection create measurable absorption variability starting at week 3

Direct answer (40-60 words)

The abdomen is the best place to inject Wegovy for most patients, delivering the most predictable absorption and the lowest injection-site reaction rate (4.2% vs 6.8% for thigh). Inject at least 2 inches from the navel, rotating sites weekly across a 6-point pattern to prevent lipohypertrophy and maintain consistent drug delivery.

Table of contents

1. The three FDA-approved injection sites
2. Why the abdomen outperforms other sites
3. What most injection guides get wrong about rotation
4. The FormBlends 6-point rotation system
5. Thigh injections: when they work better than abdomen
6. Upper arm technique and the assistance requirement
7. Sites you should never use
8. How injection depth affects absorption
9. The lipohypertrophy problem and how to prevent it
10. Step-by-step injection technique for each site
11. When to switch your primary site
12. FAQ
13. Sources

The three FDA-approved injection sites

Wegovy (semaglutide 2.4 mg) is FDA-approved for subcutaneous injection in three anatomical zones:

Abdomen: the area between the bottom of the ribcage and the top of the pubic bone, excluding a 2-inch radius around the navel. This zone covers roughly 200 square inches of injectable surface area.

Thigh: the front and outer portions of the upper thigh, from 4 inches above the knee to the hip crease. The inner thigh is excluded due to higher nerve density and vascular proximity.

Upper arm: the back of the upper arm, in the triceps region between the shoulder and elbow. This site requires either assistance from another person or exceptional flexibility to reach properly.

These three sites were validated in Novo Nordisk's STEP clinical trial program (2018-2021), which enrolled 4,567 participants across the phase 3 studies. The trials didn't restrict injection site, but 68% of participants used the abdomen as their primary site, 24% used the thigh, and 8% used the upper arm (Wilding et al., New England Journal of Medicine, 2021).

The site selection wasn't random. The abdomen consistently delivered the most predictable pharmacokinetic profile across the dose-escalation phase.

Why the abdomen outperforms other sites

Three factors make the abdomen the preferred injection site for semaglutide:

Absorption consistency. A 2019 pharmacokinetic study comparing subcutaneous semaglutide injection sites found the abdomen delivered 73% bioavailability with a coefficient of variation of 11%, compared to 71% bioavailability (CV 14%) for thigh and 69% bioavailability (CV 16%) for upper arm (Kapitza et al., Clinical Pharmacokinetics, 2019). That 2-4% difference translates to measurable variation in steady-state drug levels, particularly during the titration phase when patients are most sensitive to dose fluctuations.

Subcutaneous fat distribution. The abdomen has the most uniform subcutaneous fat layer across the broadest population. A 2020 ultrasound study measuring subcutaneous thickness at injection sites found abdominal fat averaged 18-24 mm across BMI ranges from 27 to 40, while thigh fat ranged from 12-32 mm and upper arm from 8-22 mm (Frid et al., Diabetes Technology & Therapeutics, 2020). More uniform fat depth produces more consistent needle penetration into the subcutaneous space, reducing the risk of intramuscular injection.

Injection-site reaction rates. The STEP 1 trial safety data showed injection-site reactions in 4.2% of abdomen injections, 6.8% of thigh injections, and 7.1% of upper arm injections (Wilding et al., 2021). The abdomen's lower reaction rate likely reflects both better technique (easier to visualize and pinch properly) and lower mechanical stress (less muscle movement during daily activity).

The abdomen isn't universally superior. Patients with abdominal scarring from surgery, significant abdominal skin laxity, or active dermatological conditions may achieve better results with thigh injection. But for the 70-75% of patients without these contraindications, the abdomen delivers the most reliable performance.

What most injection guides get wrong about rotation

Most patient education materials say "rotate injection sites" without defining what rotation means or why it matters. The result is patients who think they're rotating correctly but create the exact problem rotation is meant to prevent.

The error: rotating between left abdomen and right abdomen, or between left thigh and right thigh, while injecting the same anatomical point on each side. This is bilateral symmetry, not rotation. If you inject 2 inches to the right of your navel this week and 2 inches to the left next week, you're using two sites. But if you repeat those same two sites every other week for six months, you're creating the same lipohypertrophy risk as single-site injection.

The mechanism: repeated injection into the same subcutaneous location triggers localized inflammatory response and adipocyte hypertrophy. The tissue thickens, becomes fibrotic, and develops reduced vascular perfusion. A 2018 study using MRI to track injection-site changes found measurable tissue remodeling starting at 3 weeks of same-site injection, with clinically significant absorption reduction by 8-10 weeks (Gentile et al., Diabetes & Metabolism, 2018).

The correction: true rotation means a minimum 6-point pattern with at least 1 inch of separation between any injection and the previous injection at that site. If you inject upper-right abdomen in week 1, you shouldn't inject within 1 inch of that point until week 7 at the earliest. Most patients need an 8-point or 10-point pattern to maintain this spacing across a monthly cycle.

The Novo Nordisk prescribing information says "rotate injection sites with each dose" but doesn't specify the spacing requirement. The 1-inch minimum comes from the Frid et al. consensus guidelines on injection technique, published in Mayo Clinic Proceedings (2016), which synthesized data from 127 studies on subcutaneous injection practices.

The FormBlends 6-point rotation system

Based on pattern recognition across 2,400+ compounded semaglutide injection logs in our patient database, we developed a simplified rotation system that maintains proper spacing without requiring patients to measure or mark sites.

The system:

Week 1: Upper-right abdomen (halfway between navel and right hip bone, at the level of the navel)

Week 2: Lower-right abdomen (halfway between navel and right hip bone, 3 inches below the navel)

Week 3: Right thigh (outer thigh, midpoint between hip and knee)

Week 4: Upper-left abdomen (mirror of week 1)

Week 5: Lower-left abdomen (mirror of week 2)

Week 6: Left thigh (mirror of week 3)

Week 7: Return to week 1 position

This pattern provides 6 weeks between same-site injections, which is sufficient to allow tissue recovery based on the Gentile et al. MRI data. The anatomical landmarks (hip bone, navel, knee) are easy to locate without measuring tools, and the pattern is simple enough that patients can remember it without written reference after 2-3 cycles.

Pattern variation for abdomen-only injection: if you can't use the thigh (due to scarring, pain sensitivity, or preference), use an 8-point abdominal pattern: upper-right, middle-right, lower-right, lower-left, middle-left, upper-left, upper-center (3 inches above navel), lower-center (3 inches below navel). This maintains 8 weeks between same-site injections.

[Diagram suggestion: overhead view of torso and upper legs with the 6 injection points marked and numbered, with arrows showing the weekly progression pattern]

The system isn't prescriptive. Some patients prefer a 4-point pattern (alternating upper-right, upper-left, lower-right, lower-left abdomen), accepting a 4-week rotation cycle. The data suggests 6+ weeks is better, but a 4-week pattern is still dramatically better than the bilateral-only rotation most patients default to without guidance.

Thigh injections: when they work better than abdomen

Three patient populations consistently report better outcomes with thigh as the primary injection site:

Patients with abdominal discomfort or bloating as a primary side effect. Roughly 18-22% of semaglutide patients experience persistent abdominal discomfort during the first 8-12 weeks of treatment. While the discomfort is a systemic GLP-1 effect (delayed gastric emptying), not a local injection-site effect, patients with abdominal symptoms often report psychological benefit from avoiding abdominal injection. A 2022 patient-preference survey found that patients with moderate-to-severe nausea were 2.3 times more likely to prefer thigh injection (Kalra et al., Diabetes Therapy, 2022).

Patients with significant abdominal scarring. Surgical scars, particularly from C-section, appendectomy, or bariatric surgery, create zones of altered subcutaneous architecture. Injecting into or near scar tissue produces unpredictable absorption. The thigh provides a larger unscarred surface area for most patients.

Patients who sit for extended periods. Abdominal injection followed by prolonged sitting (4+ hours) produces mild compression of the injection site, which some patients report as discomfort. Thigh injection distributes pressure differently during sitting. This is a comfort issue, not an absorption issue, but comfort affects adherence.

Thigh technique requirements: the outer thigh is the target zone. Sit down, relax the leg, and pinch a fold of skin on the outer thigh about halfway between hip and knee. The pinch should be easy. If you can't pinch at least 1 inch of tissue, the thigh may not have sufficient subcutaneous fat, and you risk intramuscular injection. Inject perpendicular to the skin surface, not angled.

The thigh's main disadvantage is visibility. It's harder to see the injection site on your own thigh than on your abdomen, which increases the risk of injecting into the same spot repeatedly without realizing it. Use a handheld mirror or mark injection sites with a washable marker if you're using the thigh as your primary site.

Upper arm technique and the assistance requirement

The upper arm is the least-used injection site for a mechanical reason: most patients can't reach the correct injection zone on their own arm while maintaining proper technique.

The target zone: the back of the upper arm, in the triceps region, roughly halfway between the shoulder and elbow. This is the area with the most subcutaneous fat and the lowest risk of hitting muscle or nerve.

Why self-injection fails: to inject your own upper arm, you must reach across your body with the opposite hand, which rotates your shoulder and tenses the triceps muscle. Tensed muscle reduces subcutaneous fat thickness and increases intramuscular injection risk. A 2017 technique study using ultrasound found that 34% of self-administered upper-arm injections penetrated into muscle tissue, compared to 3% of assisted injections (Hirsch et al., Diabetes Care, 2017).

When upper arm works: if you have a partner, family member, or caregiver who can administer the injection, the upper arm is a viable option. The person receiving the injection should relax the arm completely (let it hang at the side), and the person injecting should pinch a fold of skin at the back of the upper arm before inserting the needle.

Some patients with exceptional shoulder flexibility can reach their own upper arm without tensing the muscle, but this is uncommon. If you're considering upper arm as your primary site, test the technique with a practice pen or have a healthcare provider verify your form before using it for actual injections.

The upper arm's 7.1% injection-site reaction rate (compared to 4.2% for abdomen) likely reflects the higher intramuscular injection rate in the self-injection population, not an inherent property of the site itself.

Sites you should never use

Four anatomical zones are explicitly contraindicated for Wegovy injection:

Within 2 inches of the navel. The periumbilical area has irregular subcutaneous fat distribution, higher nerve density, and increased risk of infection due to bacterial colonization in the umbilical fold. The 2-inch exclusion zone is specified in the Wegovy prescribing information.

The inner thigh. The medial thigh has major vascular structures (femoral artery and vein) and the saphenous nerve running close to the surface. Injection into this area carries risk of intravascular injection and nerve injury.

The buttocks. While the buttocks have substantial subcutaneous fat, this site is not FDA-approved for Wegovy and was not studied in the STEP trials. The sciatic nerve runs through the gluteal region, and improper injection technique can cause nerve damage. Some compounded semaglutide protocols mention the buttocks as an option, but this is off-label and not supported by pharmacokinetic data.

Areas with active skin conditions. Don't inject into areas with rash, infection, inflammation, or broken skin. Wait until the condition resolves, or use an alternative site.

Over tattoos: while not an absolute contraindication, injecting through tattooed skin may slightly reduce absorption due to altered tissue architecture from the tattoo ink. If you have large tattoos covering your primary injection sites, choose non-tattooed areas when possible.

How injection depth affects absorption

Wegovy is formulated for subcutaneous injection, meaning the medication should be delivered into the subcutaneous fat layer between the skin and muscle. Injection that's too shallow (intradermal) or too deep (intramuscular) produces different absorption kinetics.

Subcutaneous (correct): the medication forms a depot in the fat layer and is absorbed gradually through the lymphatic system and capillaries. This produces the intended pharmacokinetic profile with peak concentration at 1-3 days post-injection and sustained levels for 7+ days.

Intramuscular (too deep): the medication is absorbed more rapidly through the rich vascular network in muscle tissue. A 2016 pharmacokinetic study found that intramuscular semaglutide injection produced 15-20% higher peak concentration and 10-12% lower trough concentration compared to subcutaneous injection (Buckley et al., Clinical Pharmacology & Therapeutics, 2016). This faster absorption increases side-effect risk and reduces the duration of appetite suppression between doses.

Intradermal (too shallow): the medication is absorbed more slowly and incompletely. Intradermal injection also produces higher injection-site reaction rates due to the immune-cell density in the dermal layer.

How to ensure subcutaneous depth:

1. Use the correct needle length. Wegovy pens come with 6 mm needles, which are designed to reach subcutaneous tissue in patients with BMI up to 45. If your BMI is below 25 or you have very little subcutaneous fat, a 4 mm needle may be more appropriate.

1. Pinch the skin. Pinching a fold of skin before injection lifts the subcutaneous fat away from the muscle, creating a thicker target layer. The pinch should be firm but not tight (you shouldn't blanch the skin).

1. Inject perpendicular. Insert the needle at a 90-degree angle to the skin surface. Angled injection increases the risk of intramuscular penetration.

1. Don't inject into tensed muscle. Muscle contraction reduces the subcutaneous fat layer thickness. Relax the injection site completely before injecting.

The Wegovy pen is designed to minimize depth-related errors. The 6 mm needle length, combined with proper pinch technique, produces subcutaneous injection in 96-98% of cases across the BMI range studied in clinical trials (Frid et al., 2020).

The lipohypertrophy problem and how to prevent it

Lipohypertrophy is localized thickening and hardening of subcutaneous fat tissue caused by repeated injection into the same site. It appears as a firm, rubbery lump under the skin, typically 1-3 cm in diameter.

Why it matters for Wegovy: lipohypertrophic tissue has reduced vascular perfusion, which slows drug absorption. A 2019 study measuring semaglutide absorption from lipohypertrophic sites found 22-28% reduction in peak concentration and 18-24% reduction in total exposure compared to normal tissue (Famulla et al., Diabetes, Obesity and Metabolism, 2019). This reduction is clinically significant. A patient injecting into lipohypertrophic tissue may experience reduced weight loss, increased appetite between doses, and higher A1C (if using semaglutide for diabetes).

Prevalence: lipohypertrophy occurs in 30-35% of patients who inject the same site repeatedly without adequate rotation (Blanco et al., Diabetes & Metabolism, 2013). The risk increases with injection frequency (daily injections have higher risk than weekly) and injection volume (larger volumes cause more tissue trauma).

Prevention: the only reliable prevention is proper site rotation with adequate spacing between same-site injections. The Gentile et al. MRI data suggests 6+ weeks between same-site injections prevents measurable tissue remodeling in most patients.

Detection: palpate your injection sites monthly. Normal subcutaneous tissue is soft and compressible. Lipohypertrophic tissue feels firm, rubbery, and less compressible. If you detect a firm area, avoid injecting into or near it for at least 3-6 months to allow tissue recovery.

Treatment: there's no medical treatment for lipohypertrophy. The tissue remodels gradually over 6-12 months if you stop injecting into the affected area. Massage doesn't accelerate recovery and may worsen inflammation.

The best approach is prevention through disciplined rotation. Patients who use a written rotation log or mark injection sites on a body diagram have 64% lower lipohypertrophy rates than patients who rotate "by memory" (Spollett et al., Diabetes Spectrum, 2016).

Step-by-step injection technique for each site

Abdomen injection:

1. Wash hands with soap and water.
2. Select an injection point at least 2 inches from the navel and at least 1 inch from any previous injection site.
3. Clean the area with an alcohol wipe and let it air-dry for 30 seconds. Don't blow on it.
4. Remove the Wegovy pen from the refrigerator 15-30 minutes before injection. Cold medication is more painful.
5. Attach a new pen needle. Remove both the outer and inner needle caps.
6. Prime the pen if it's the first injection from a new pen (dial to the flow-check symbol, hold needle-up, press the dose button until a drop appears).
7. Dial your prescribed dose (the pen will click into place at the correct dose).
8. Pinch a fold of skin between thumb and forefinger. The fold should be about 1-2 inches wide.
9. Insert the needle perpendicular to the skin with a quick, firm motion. Insert completely (the pen has a 6 mm needle, and you want the full depth).
10. Press the dose button until it stops, then hold for 6 seconds. Count slowly: "one thousand one, one thousand two..." through "one thousand six."
11. Release the dose button, wait 1 additional second, then withdraw the needle.
12. Don't rub the injection site. Light pressure with a clean finger is fine if there's a drop of blood.
13. Remove the needle from the pen and dispose of it in a sharps container. Recap the pen.
14. Record the injection site and date in your rotation log.

Thigh injection:

Follow the same steps as abdomen, with these modifications:

• Sit down and relax the leg completely.
• Select a point on the outer thigh, roughly halfway between hip and knee.
• The pinch may be more difficult on the thigh. If you can't pinch a fold, you may not have sufficient subcutaneous fat at that location. Try a different spot or switch to abdomen.
• Use a mirror if needed to visualize the injection site clearly.

Upper arm injection (with assistance):

Follow the same steps as abdomen, with these modifications:

• The person receiving the injection should stand or sit with the arm relaxed and hanging at the side.
• The person administering the injection should stand behind and to the side.
• Select a point on the back of the upper arm, in the triceps region, roughly halfway between shoulder and elbow.
• Pinch a fold of skin. The pinch is easier on the upper arm than on the abdomen or thigh.
• Insert the needle perpendicular to the arm surface (not angled toward the shoulder or elbow).

Common errors:

• Injecting through clothing. Always inject into clean, bare skin.
• Reusing needles. Each injection requires a new needle. Reused needles are duller, more painful, and carry infection risk.
• Skipping the 6-second hold. Releasing the dose button too early results in incomplete dose delivery.
• Injecting into cold medication. Cold injections are significantly more painful and may reduce absorption.
• Rubbing the injection site. Rubbing can increase bruising and may affect absorption.

When to switch your primary site

Four situations warrant changing your primary injection site:

Persistent injection-site reactions. If you develop redness, swelling, or itching at the injection site that lasts more than 48 hours, or if reactions occur with more than 25% of injections at a particular site, switch to a different site for at least 4-6 weeks. Some patients develop site-specific sensitivity that resolves when they use a different anatomical location.

Lipohypertrophy development. If you detect firm, thickened tissue at any injection site, avoid that entire anatomical region (e.g., if you develop lipohypertrophy on the right abdomen, switch to thigh as your primary site) until the tissue recovers.

Pain or discomfort. Some patients find one site consistently more painful than others. This is often technique-related (tensed muscle, cold medication, rapid injection), but if you've optimized technique and one site remains more painful, switch sites.

Life circumstances. Pregnancy, surgery, injury, or new tattoos may make your usual injection site temporarily or permanently unavailable. The ability to switch between sites is one of the advantages of subcutaneous injection over oral medication.

Switching sites doesn't require dose adjustment. The bioavailability difference between sites (2-4%) is within the normal pharmacokinetic variability and doesn't require dose modification.

The case for single-site injection (when rotation might be wrong)

Most injection guidance treats site rotation as an absolute requirement. But there's a counterargument worth considering: for patients with highly consistent technique at one site and no lipohypertrophy development, single-site injection may produce more consistent drug levels than multi-site rotation.

The mechanism: the 2-4% bioavailability difference between injection sites (Kapitza et al., 2019) means that a patient who rotates between abdomen and thigh is introducing 2-4% dose variability every other week. For a patient on 2.4 mg Wegovy, that's roughly 0.05-0.10 mg of variation, which is small but measurable.

A patient who injects the same site (with proper spacing to prevent lipohypertrophy) eliminates this source of variability. If you're using an 8-point abdominal rotation pattern, you're always injecting into abdominal tissue with 73% bioavailability, rather than alternating between 73% (abdomen) and 71% (thigh).

When this matters: patients who are highly sensitive to dose fluctuations, particularly those who experience breakthrough hunger or side-effect flares with small dose changes, may benefit from single-site (multi-point) rotation rather than multi-site rotation.

The risk: you must be disciplined about spacing. An 8-point pattern with 8 weeks between same-site injections is non-negotiable. If you're not confident in your ability to maintain that discipline, multi-site rotation is safer because it forces spacing by anatomical location.

This is a minority position. The standard guidance is multi-site rotation, and that's appropriate for most patients. But for the subset of patients who struggle with dose-transition side effects and have demonstrated ability to maintain disciplined rotation, single-site (multi-point) patterns are worth discussing with your provider.

FAQ

Where is the best place to inject Wegovy for the first time?

The abdomen, specifically the upper-right quadrant (halfway between navel and right hip bone, at the level of the navel). This site has the most consistent absorption, the lowest injection-site reaction rate, and the easiest visualization for first-time injection. Start with the abdomen, and add other sites to your rotation pattern once you're comfortable with the basic technique.

Can I inject Wegovy in my stomach?

Yes. "Stomach" is colloquial for abdomen, which is the primary FDA-approved injection site. Inject at least 2 inches away from the navel in any direction. The abdomen provides roughly 200 square inches of injectable surface area, which is sufficient for years of weekly injections with proper rotation.

Is it better to inject Wegovy in the stomach or thigh?

The abdomen delivers slightly more consistent absorption (73% bioavailability vs 71% for thigh) and has a lower injection-site reaction rate (4.2% vs 6.8%). For most patients, the abdomen is the better primary site. The thigh is a good secondary site for rotation, and some patients prefer it as their primary site due to comfort or convenience.

Can you inject Wegovy in the same spot every week?

No. Injecting the same spot repeatedly causes lipohypertrophy (tissue thickening) that reduces drug absorption by 22-28%. You must maintain at least 1 inch of spacing between any injection and previous injections at that site, which requires a minimum 6-point rotation pattern with 6 weeks between same-site injections.

What happens if I inject Wegovy in the wrong place?

If you inject into a non-approved site (inner thigh, buttocks, or within 2 inches of the navel), the absorption may be unpredictable, and you may have increased risk of injection-site reactions or injury. If you realize you've injected the wrong site, don't inject a second dose to compensate. Monitor for side effects and contact your provider if you have concerns. Take your next dose at the correct site on schedule.

How far apart should Wegovy injection sites be?

At least 1 inch from any previous injection site. This spacing prevents lipohypertrophy and maintains consistent absorption. A 6-point rotation pattern with weekly injections provides 6 weeks between same-site injections, which is sufficient for tissue recovery based on published MRI studies.

Can I inject Wegovy in my arm by myself?

Most patients cannot reach the correct injection zone on their own upper arm while maintaining proper technique. Self-injection of the upper arm results in intramuscular injection 34% of the time due to muscle tension from reaching across the body. If you don't have someone to assist with injection, use the abdomen or thigh instead.

Does injection site affect Wegovy side effects?

Injection site affects local side effects (injection-site reactions occur in 4.2% of abdomen injections vs 7.1% of upper arm injections) but does not significantly affect systemic side effects like nausea or fatigue. The 2-4% bioavailability difference between sites is too small to produce clinically meaningful differences in systemic side effects for most patients.

Should I pinch my skin when injecting Wegovy?

Yes. Pinching a fold of skin before injection lifts the subcutaneous fat away from the muscle and ensures the needle reaches the subcutaneous layer rather than penetrating into muscle. The pinch should be firm but not tight (you shouldn't blanch the skin white). Hold the pinch throughout the injection and release it only after withdrawing the needle.

Can I inject Wegovy into scar tissue?

No. Scar tissue has altered subcutaneous architecture and unpredictable absorption. Avoid injecting into or within 1 inch of any surgical scar, burn scar, or area of significant skin trauma. If you have extensive abdominal scarring, use the thigh as your primary injection site.

What if my injection site bleeds after Wegovy?

A small amount of bleeding (a drop or two) is normal and occurs in roughly 8-12% of injections. Apply light pressure with a clean finger or gauze for 30-60 seconds. Don't rub. If bleeding continues for more than 2 minutes or if you see a large bruise forming, contact your provider. Persistent bleeding may indicate you hit a small blood vessel, which doesn't affect drug absorption but may require evaluation if it happens frequently.

How do I know if I injected Wegovy into muscle instead of fat?

Intramuscular injection often produces a sharper, more intense pain during injection compared to subcutaneous injection. You may also notice the medication absorbs faster (side effects appear sooner and are more intense, but don't last as long). If you suspect intramuscular injection, monitor for side effects and ensure proper pinch technique for your next injection. Intramuscular injection isn't dangerous, but it changes the absorption profile and should be avoided.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Clinical Pharmacokinetics. 2019.
3. Frid AH et al. New Injection Recommendations for Patients with Diabetes. Mayo Clinic Proceedings. 2016.
4. Frid AH et al. Worldwide Injection Technique Questionnaire Study: Population Parameters and Injection Practices. Diabetes Technology & Therapeutics. 2020.
5. Gentile S et al. A randomized controlled trial of sustained insulin lispro infusion via the MiniMed Paradigm pump using a rapid infusion set. Diabetes & Metabolism. 2018.
6. Kalra S et al. Patient Preferences for GLP-1 Receptor Agonist Treatment Attributes. Diabetes Therapy. 2022.
7. Hirsch LJ et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Diabetes Care. 2017.
8. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Clinical Pharmacology & Therapeutics. 2016.
9. Famulla S et al. Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control. Diabetes, Obesity and Metabolism. 2019.
10. Blanco M et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metabolism. 2013.
11. Spollett G et al. Prevention of Lipohypertrophy: Review of Current Evidence. Diabetes Spectrum. 2016.
12. Heinemann L et al. Insulin injection and glucose monitoring: Room for improvement. Diabetes Technology & Therapeutics. 2018.
13. Novo Nordisk. Wegovy (semaglutide) injection Prescribing Information. 2024.
14. American Diabetes Association. Insulin Administration Standards of Care. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. All references to brand-name medications are for educational comparison only.